Jacobs Levy Equity Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Jacobs Levy Equity Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.93M	Sell	41,593 -1,133	-3%	-$54.4K	0.01%	601
2026 Q1	$2.21M	Sell	42,726 -83,491	-66%	-$4.25M	0.01%	568
2025 Q4	$6.27M	Buy	126,217 +87,044	+222%	+$4.23M	0.02%	365
2025 Q3	$1.87M	Buy	+39,173	New	+$1.58M	0.01%	606
2021 Q1	–	Sell	-683,835	Closed	-$17.2M	–	1112
2020 Q4	$17.2M	Buy	683,835 +136,537	+25%	+$2.94M	0.15%	165
2020 Q3	$11.4M	Buy	547,298 +90,717	+20%	+$2.06M	0.12%	192
2020 Q2	$10.8M	Buy	456,581 +404,362	+774%	+$8.93M	0.12%	202
2020 Q1	$939K	Buy	+52,219	New	+$1.1M	0.01%	640
2018 Q2	–	Sell	-12,710	Closed	-$582K	–	1100
2018 Q1	$582K	Buy	+12,710	New	+$530K	0.01%	753
2015 Q2	–	Sell	-15,600	Closed	-$189K	–	859
2015 Q1	$189K	Buy	+15,600	New	+$147K	﹤0.01%	709

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Jacobs Levy Equity Management's SUPN Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Supernus Pharmaceuticals (SUPN) stake by 2.7% in Q2 2026, selling an estimated $54.4K and leaving 41,593 shares worth $1.93M. The position accounts for 0.01% of the portfolio, ranked #601.

Jacobs Levy Equity Management first reported a position in SUPN in Q1 2015 and has held it in 10 quarters since. The position peaked at $17.2M in Q4 2020. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Jacobs Levy Equity Management held 41,593 shares of Supernus Pharmaceuticals worth $1.93M as of Q2 2026.
Jacobs Levy Equity Management sold 1,133 Supernus Pharmaceuticals shares in Q2 2026, an estimated $54.4K.
Supernus Pharmaceuticals made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #601 holding.
Jacobs Levy Equity Management first reported a position in Supernus Pharmaceuticals in Q1 2015 and has held it in 10 quarters since.
Jacobs Levy Equity Management's Supernus Pharmaceuticals position peaked at $17.2M in Q4 2020.
334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.